About: Enhancement of blood-brain barrier permeability is required for intravenously administered virus neutralizing antibodies to clear an established rabies virus infection from the brain and prevent the development of rabies in mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Enhancement of blood-brain barrier permeability is required for intravenously administered virus neutralizing antibodies to clear an established rabies virus infection from the brain and prevent the development of rabies in mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Enhancement of blood-brain barrier permeability is required for intravenously administered virus neutralizing antibodies to clear an established rabies virus infection from the brain and prevent the development of rabies in mice
Creator	Huang, Ying Zhou, Ming Wu, Hua Chai, Qingqing Zhang, Guoqing Fu, Zhen Huang, Chien-Tsun Li, Zhenguang
source	Elsevier; Medline; PMC
abstract	Rabies virus (RABV) is a neurotropic virus that causes fatal disease in humans and animals. Currently there is no cure for rabies once clinical signs appear. It is believed that once RABV enters the central nervous system (CNS), virus neutralizing antibodies (VNAs) in the periphery cannot pass through the Blood–brain Barrier (BBB) and into the CNS. Furthermore, it has been hypothesized that VNAs produced in the CNS by invading B cells, rather than those produced in the periphery and then transported into the CNS, are important in clearing RABV from the CNS. In the present study, mouse serum containing VNA was administered intravenously into mice after infection with wild-type RABV. Our studies demonstrate that exogenous administration of VNAs is crucial in the clearance of RABV from the brain and prevent the development of rabies in both immunocompetent and immunocompromised mice as long as the BBB permeability remains enhanced. This present study therefore provides a foundation for the possibility of developing VNA therapy for clinical rabies in humans.
has issue date	2014-10-01(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2014.07.013
bibo:pmid	25108172
has license	green-oa
sha1sum (hex)	25fcf9b7042d134127c272d27f5a4dda16e0c5ff
schema:url	https://doi.org/10.1016/j.antiviral.2014.07.013
resource representing a document's title	Enhancement of blood-brain barrier permeability is required for intravenously administered virus neutralizing antibodies to clear an established rabies virus infection from the brain and prevent the development of rabies in mice
has PubMed Central identifier	PMC4171353
has PubMed identifier	25108172
schema:publication	Antiviral Research
resource representing a document's body	covid:25fcf9b7042d134127c272d27f5a4dda16e0c5ff#body_text
is schema:about of	named entity 'CNS' named entity 'clinical signs' named entity 'believed' named entity 'brain' named entity 'developing' named entity 'clearing' named entity 'CNS' named entity 'rabies' named entity 'enhanced' named entity 'demonstrate' named entity 'mice' named entity 'virus' named entity 'administered intravenously' named entity 'exogenous administration' named entity 'central nervous' named entity 'immunocompromised' named entity 'permeability' named entity 'BBB' named entity 'neutralizing antibodies' named entity 'blood-brain barrier' named entity 'permeability' named entity 'rabies' named entity 'infection' named entity 'BBB' named entity 'BBB' named entity 'ICR mice' named entity 'MCP-1' named entity 'MCP-1' named entity 'BBB' named entity 'Statistical significance' named entity 'rabies infection' named entity 'mice' named entity 'MCP-1' named entity 'mRNA' named entity 'light chain' named entity 'MCP-1' named entity 'IgG' named entity 'immunoreactive' named entity 'infection' named entity 'PEP' named entity 'mice' named entity 'titration' named entity 'CNS' named entity 'BBB' named entity 'BBB' named entity 'PBS' named entity 'Dog' named entity 'MCP-1' named entity 'pathogens' named entity 'National Institutes of Health' named entity 'anti-viral' named entity 'clinical signs' named entity 'acetone' named entity 'Bioscience' named entity 'mice' named entity 'inflammatory cells' named entity 'mice' named entity 'DNase' named entity 'Fluorescing' named entity 'rabies' named entity 'encephalomyelitis' named entity 'antibody' named entity 'C57BL/6J' named entity 'rabies' named entity 'tight junction' named entity 'B-cell' named entity 'biceps femoris muscle' named entity 'antibody' named entity 'mice' named entity 'Intravenous administration' named entity 'RNA' named entity 'serum' named entity 'homogenates' named entity 'mice'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software